Hester Biosciences Ltd
NSE: HESTERBIO BSE: 524669
₹1530.10
(-1.11)%
Wed, 11 Feb 2026, 02:37 pm
Market Cap13.17B
PE Ratio31.79
Dividend0.45
Health Technology
Pharmaceuticals: Major
24.5KAnalysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (4.4x coverage).
- Hester Biosciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Hester Biosciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Hester Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Hester Biosciences is profitable, therefore cash runway is not a concern.
- Hester Biosciences is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (56.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.5x debt.
- Hester Biosciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (62.1% vs 56.5% today).
- Interest payments on debt are well covered by earnings (EBIT is 10.8x coverage).
- Hester Biosciences's level of debt (56.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Hester Biosciences board of directors is about average.
- Rajiv's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Hester Biosciences management team is about average.
- Rajiv's remuneration is higher than average for companies of similar size in India.
misc
- Hester Biosciences is not covered by any analysts.
past
- Hester Biosciences has delivered over 20% year on year earnings growth in the past 5 years.
- Hester Biosciences used its assets more efficiently than the IN Biotechs industry average last year based on Return on Assets.
- Hester Biosciences has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Hester Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Hester Biosciences's earnings growth has exceeded the Asia Biotechs industry average in the past year (5.2% vs -5.4%).
- Hester Biosciences's 1-year earnings growth is less than its 5-year average (5.2% vs 20.4%)
value
- Hester Biosciences is good value based on earnings compared to the IN Biotechs industry average.
- Hester Biosciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Hester Biosciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Hester Biosciences is overvalued based on assets compared to the IN Biotechs industry average.
- Hester Biosciences is overvalued based on earnings compared to the India market.
- 524669 underperformed the Biotechs industry which returned 53.2% over the past year.
- 524669 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524669 is up 6.2% underperforming the Biotechs industry which returned 18.2% over the past month.
- BSE:524669 is up 6.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800